MARK A. GOLDSMITH - 06 Feb 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
President and Chief Executive Officer, Director
Signature
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith
Issuer symbol
RVMD
Transactions as of
06 Feb 2026
Net transactions value
+$12,965
Form type
4
Filing time
10 Feb 2026, 17:30:31 UTC
Previous filing
18 Dec 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GOLDSMITH MARK A President and Chief Executive Officer, Director C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY /s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith 10 Feb 2026 0001246842

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $12,965 +24,010 +10% $0.5400 256,479 06 Feb 2026 Direct F1
holding RVMD Common Stock 570,050 06 Feb 2026 Trust F2
holding RVMD Common Stock 67,424 06 Feb 2026 Trust F3
holding RVMD Common Stock 67,424 06 Feb 2026 Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -24,010 -14% $0.000000 144,493 06 Feb 2026 Common Stock 24,010 $0.5400 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 168,763 restricted stock units.
F2 Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
F3 Held by Jonathan Goldsmith Revocable Trust.
F4 Held by Rebecca Goldsmith Revocable Trust.

Remarks:

President and Chief Executive Officer